Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
27 01 2021
Historique:
received: 21 02 2020
accepted: 09 12 2020
entrez: 28 1 2021
pubmed: 29 1 2021
medline: 20 8 2021
Statut: epublish

Résumé

Vision restoration is an ideal medical application for optogenetics, because the eye provides direct optical access to the retina for stimulation. Optogenetic therapy could be used for diseases involving photoreceptor degeneration, such as retinitis pigmentosa or age-related macular degeneration. We describe here the selection, in non-human primates, of a specific optogenetic construct currently tested in a clinical trial. We used the microbial opsin ChrimsonR, and showed that the AAV2.7m8 vector had a higher transfection efficiency than AAV2 in retinal ganglion cells (RGCs) and that ChrimsonR fused to tdTomato (ChR-tdT) was expressed more efficiently than ChrimsonR. Light at 600 nm activated RGCs transfected with AAV2.7m8 ChR-tdT, from an irradiance of 10

Identifiants

pubmed: 33504896
doi: 10.1038/s42003-020-01594-w
pii: 10.1038/s42003-020-01594-w
pmc: PMC7840970
doi:

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

125

Références

Arq Bras Oftalmol. 2007 Jan-Feb;70(1):91-9
pubmed: 17505726
Nat Methods. 2014 Mar;11(3):338-46
pubmed: 24509633
J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1250-65
pubmed: 17429471
Ophthalmology. 2012 Apr;119(4):779-88
pubmed: 22244176
Neuron. 2019 Mar 6;101(5):839-862
pubmed: 30844402
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6177-82
pubmed: 15837919
Mol Ther. 2011 Jul;19(7):1220-9
pubmed: 21505421
Mol Ther. 2015 Jan;23(1):7-16
pubmed: 25095892
Proc Natl Acad Sci U S A. 1933 May;19(5):522-35
pubmed: 16587779
Ophthalmology. 2018 Jun;125(6):945-947
pubmed: 29426586
Nat Commun. 2018 May 1;9(1):1750
pubmed: 29717130
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5288-96
pubmed: 20484599
J Neural Eng. 2009 Jun;6(3):035007
pubmed: 19458396
Lancet. 2016 Aug 13;388(10045):661-72
pubmed: 27375040
Vision Res. 1990;30(11):1897-911
pubmed: 2288097
Nat Neurosci. 2008 Jun;11(6):667-75
pubmed: 18432197
Front Cell Neurosci. 2016 Apr 28;10:103
pubmed: 27199657
Ophthalmology. 2016 Oct;123(10):2248-54
pubmed: 27453256
J Neurosci. 2015 Mar 18;35(11):4663-75
pubmed: 25788683
Vision Res. 2000;40(14):1801-11
pubmed: 10837827
Front Neurosci. 2018 Nov 02;12:789
pubmed: 30450028
Appl Opt. 1995 Aug 1;34(22):4912-22
pubmed: 21052333
Nature. 2010 Apr 15;464(7291):1006-11
pubmed: 20228791
Invest Ophthalmol Vis Sci. 2012 Jan 20;53(1):205-14
pubmed: 22110084
Vision Res. 2003 Nov;43(24):2573-81
pubmed: 13129543
Prog Retin Eye Res. 2003 Sep;22(5):607-55
pubmed: 12892644
Neuron. 2019 May 8;102(3):574-586.e5
pubmed: 30876849
J Comp Neurol. 1991 Jan 22;303(4):617-36
pubmed: 1707423
Nat Med. 2015 May;21(5):476-82
pubmed: 25915832
Science. 2010 Jul 23;329(5990):413-7
pubmed: 20576849
Front Syst Neurosci. 2019 Feb 01;12:73
pubmed: 30774585
J Biomed Semantics. 2016 Mar 30;7:15
pubmed: 27034769
JCI Insight. 2018 Jan 25;3(2):
pubmed: 29367457
Vision Res. 1995 Aug;35(16):2245-54
pubmed: 7571461
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3364-71
pubmed: 17591910
Transl Pediatr. 2015 Apr;4(2):139-63
pubmed: 26835369
Mol Ther. 2018 Sep 5;26(9):2282-2294
pubmed: 30196853
Sci Transl Med. 2013 Jun 12;5(189):189ra76
pubmed: 23761039
Invest Ophthalmol Vis Sci. 2011 Apr 25;52(5):2775-83
pubmed: 21310920
Annu Rev Chem Biomol Eng. 2017 Jun 7;8:13-39
pubmed: 28592174
PLoS Comput Biol. 2020 Jul 15;16(7):e1007857
pubmed: 32667921
Nat Neurosci. 2011 Apr;14(4):513-8
pubmed: 21399632
Front Neurosci. 2017 Aug 23;11:445
pubmed: 28878616
Front Neurosci. 2015 Feb 24;9:46
pubmed: 25759637
Front Neurosci. 2019 Aug 16;13:865
pubmed: 31474825
EMBO Mol Med. 2016 Nov 2;8(11):1248-1264
pubmed: 27679671
Proc Biol Sci. 2011 May 22;278(1711):1489-97
pubmed: 21047851
Mol Ther. 2017 Nov 1;25(11):2546-2560
pubmed: 28807567
Nat Biotechnol. 2004 Dec;22(12):1567-72
pubmed: 15558047
Science. 2020 Jun 5;368(6495):1108-1113
pubmed: 32499439
Vision Res. 2016 Apr;121:57-71
pubmed: 26882975
Nat Commun. 2016 Jun 16;7:11928
pubmed: 27306044
Vision Res. 2015 Jun;111(Pt B):149-60
pubmed: 25812924
Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5995-6003
pubmed: 21693599
Neuron. 2006 Apr 6;50(1):23-33
pubmed: 16600853
Nat Biomed Eng. 2020 Feb;4(2):172-180
pubmed: 31792423
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9666-70
pubmed: 1409680

Auteurs

Gregory Gauvain (G)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France. gregory.gauvain@inserm.fr.

Himanshu Akolkar (H)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.
Department of Ophthalmology, University Pittsburgh Medical Center, Pittsburgh, PA, USA.

Antoine Chaffiol (A)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Fabrice Arcizet (F)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Mina A Khoei (MA)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Mélissa Desrosiers (M)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Céline Jaillard (C)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Romain Caplette (R)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Olivier Marre (O)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Stéphane Bertin (S)

CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, 28 rue de Charenton, F-75012, Paris, France.

Claire-Maelle Fovet (CM)

Département des Sciences du Vivant (DSV), MIRcen, Institut d'imagerie Biomédicale (I2BM), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 92260, Fontenay-aux-Roses, France.

Joanna Demilly (J)

Département des Sciences du Vivant (DSV), MIRcen, Institut d'imagerie Biomédicale (I2BM), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 92260, Fontenay-aux-Roses, France.

Valérie Forster (V)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Elena Brazhnikova (E)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Philippe Hantraye (P)

Département des Sciences du Vivant (DSV), MIRcen, Institut d'imagerie Biomédicale (I2BM), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 92260, Fontenay-aux-Roses, France.

Pierre Pouget (P)

ICM, UMRS 1127 UPMC - U 1127 INSERM - UMR 7225 CNRS, Paris, France.

Anne Douar (A)

Gensight Biologics, 74 rue du faubourg Saint Antoine, F-75012, Paris, France.

Didier Pruneau (D)

Gensight Biologics, 74 rue du faubourg Saint Antoine, F-75012, Paris, France.

Joël Chavas (J)

Gensight Biologics, 74 rue du faubourg Saint Antoine, F-75012, Paris, France.

José-Alain Sahel (JA)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.
Department of Ophthalmology, University Pittsburgh Medical Center, Pittsburgh, PA, USA.
CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, 28 rue de Charenton, F-75012, Paris, France.

Deniz Dalkara (D)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Jens Duebel (J)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.

Ryad Benosman (R)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.
Department of Ophthalmology, University Pittsburgh Medical Center, Pittsburgh, PA, USA.

Serge Picaud (S)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France. serge.picaud@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH